TIDMHCM
RNS Number : 9354W
Hutchison China Meditech Limited
28 April 2021
Results of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April
28, 2021: Hutchison China MediTech Limited ("HUTCHMED" or the
"Company") (Nasdaq/AIM: HCM) today announces that all ordinary
resolutions and special resolutions put to its Annual General
Meeting ("AGM") held on April 28, 2021 were duly passed. The poll
results of the resolutions were as follows:
Number of Votes (%)*
Resolutions For Against Withheld(#)
To consider and adopt the audited
financial statements and the reports
of the directors and independent
auditor for the year ended December
1 31, 2020. 630,497,481 57,834,970 1,916,690
(91.5978%) (8.4022%)
2(A) To re-elect Mr Simon To as a director. 582,822,673 78,632,253 28,794,215
(88.1122%) (11.8878%)
To re-elect Mr Christian Hogg as
2(B) a director. 687,962,021 2,278,095 9,025
(99.6700%) (0.3300%)
To re-elect Mr Johnny Cheng as a
2(C) director. 686,432,366 3,805,770 11,005
(99.4486%) (0.5514%)
2(D) To re-elect Dr Weiguo Su as a director. 687,380,226 2,859,890 9,025
(99.5857%) (0.4143%)
2(E) To re-elect Dr Dan Eldar as a director. 650,371,921 39,867,120 10,100
(94.2242%) (5.7758%)
2(F) To re-elect Ms Edith Shih as a director. 650,086,941 39,934,200 228,000
(94.2126%) (5.7874%)
2(G) To re-elect Mr Paul Carter as a director. 605,583,736 84,654,830 10,575
(87.7354%) (12.2646%)
To re-elect Dr Karen Ferrante as
2(H) a director. 621,140,866 69,096,195 12,080
(89.9895%) (10.0105%)
2(I) To re-elect Mr Graeme Jack as a director. 605,033,971 85,199,140 16,030
(87.6565%) (12.3435%)
To re-elect Professor Tony Mok as
2(J) a director. 649,699,566 40,540,520 9,055
(94.1266%) (5.8734%)
To re-appoint PricewaterhouseCoopers
as the auditor of the Company and
authorize the board of directors
3 to fix the auditor's remuneration. 689,797,116 436,820 15,205
(99.9367%) (0.0633%)
To grant a general
mandate to the
directors of the
Ordinary Resolution Company to issue
4 No. 4(A) : additional shares. 687,700,756 2,537,355 11,030
(99.6324%) (0.3676%)
To disapply pre-emption
Special Resolution rights (general
No. 4(B) : power). 685,992,219 4,237,012 19,910
(99.3861%) (0.6139%)
To disapply pre-emption
rights (in connection
Special Resolution with an equity
No. 4(C) : raise). 574,881,172 115,343,064 24,905
(83.2890%) (16.7110%)
To grant a general
mandate to the
directors of the
Ordinary Resolution Company to repurchase
No. 4(D) : shares of the Company. 689,852,331 370,175 26,635
(99.9464%) (0.0536%)
To change the English
name of the Company
to "HUTCHMED (China)
Limited" and the
Chinese name of
the Company to
5 Special Resolution : " ". 690,238,916 2,195 8,030
(99.9997%) (0.0003%)
* Percentages rounded to 4 decimal places
(#) A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of the votes for and against a
resolution.
The change of name will be effective once the Register of
Companies has issued a certificate of incorporation on change of
name.
As at the date of the AGM, the number of issued shares of
HUTCHMED was 744,515,660, which was the total number of shares
entitling the holders to attend and vote on the ordinary
resolutions and special resolutions proposed at the AGM.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and
global development and commercialization of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. A dedicated organization of over 1,200 personnel has
advanced ten cancer drug candidates from in-house discovery into
clinical studies around the world, with its first two oncology
drugs now approved and launched. For more information, please
visit: www.hutch-med.com or follow us on LinkedIn .
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile) / +852 97 83 6894 (Mobile)
HUTCHMED@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSESFDAEFSEFL
(END) Dow Jones Newswires
April 28, 2021 09:20 ET (13:20 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
